MNOV - MediciNova, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.09
+0.34 (+3.16%)
As of 10:20AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close10.75
Open11.00
Bid10.64 x 1200
Ask10.72 x 800
Day's Range10.63 - 11.11
52 Week Range6.68 - 12.91
Volume44,710
Avg. Volume68,324
Market Cap467.685M
Beta (3Y Monthly)1.88
PE Ratio (TTM)N/A
EPS (TTM)-0.36
Earnings DateApr 26, 2017 - May 1, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Trade prices are not sourced from all markets
  • GlobeNewswire15 hours ago

    MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of glioblastoma. The allowed claims cover a method of treating a patient diagnosed with glioblastoma or recurrent glioblastoma using MN-166 (ibudilast) as part of a combination therapy.

  • Benzinga8 days ago

    The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic Alternatives

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 15) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Biohaven ...

  • GlobeNewswire9 days ago

    MediciNova Announces Plans to Move Forward with a Phase 3 Trial of MN-166 (ibudilast) in ALS

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the protocol and determined that MediciNova may proceed with a Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). If this potentially pivotal trial is successful, the Phase 2b/3 efficacy and safety data is intended to support a New Drug Application (NDA) for MN-166 (ibudilast) in ALS.

  • Zacks Small Cap Research16 days ago

    MNOV: New Analysis Shows Efficacy of MN-166 in Non-Relapsing SPMS…

    The SPRINT-MS trial was a Phase 2b clinical trial of patients with either secondary progressive MS (SPMS) or primary progressive MS (PPMS) in which participants received either MN-166 (100 mg/day) or placebo twice a day for a total of 96 weeks of treatment. The company has previously reported positive results from the SPRINT-MS trial, as it achieved both primary endpoints (a statistically significant 48% reduction in the rate of progression of whole brain atrophy along with safety and tolerability) and also demonstrated effects on important secondary endpoints including a positive trend of a 26% reduction in confirmed disability progression, which would be a primary endpoint in a Phase 3 trial.

  • GlobeNewswire21 days ago

    MediciNova Receives Notice of Allowance for New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in China

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Chinese Patent Office for a pending patent application which covers MN-001 (tipelukast) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2034.  The allowed claims cover the use of MN-001 for reducing a triglyceride blood level, the use of MN-001 for reducing a total cholesterol blood level, and the use of MN-001 for reducing a low density lipoprotein (LDL) blood level.  The allowed claims cover oral administration including liquid and solid dosage forms.

  • GlobeNewswire23 days ago

    MediciNova Announces Results of Subgroup Analysis from the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS

    LA JOLLA, Calif., April 01, 2019 -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock.

  • GlobeNewswirelast month

    MediciNova Announces Upcoming Presentations Regarding the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive Multiple Sclerosis at the 71st American Academy of Neurology Annual Meeting in Philadelphia, Pennsylvania

    LA JOLLA, Calif., March 24, 2019 -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock.

  • GlobeNewswire2 months ago

    MediciNova Announces MN-001 Research Collaboration with The Jikei University School of Medicine in Tokyo, Japan

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it will initiate a comprehensive research collaboration to evaluate MN-001 (tipelukast) in liver diseases with the Division of Gastroenterology and Hepatology at The Jikei University School of Medicine in Tokyo, Japan. Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc., commented, “We are very pleased to initiate this collaboration with researchers at The Jikei University evaluating MN-001 in various liver diseases. Multiple animal model studies of MN-001 have demonstrated its anti-fibrotic and anti-inflammatory effects.

  • GlobeNewswire2 months ago

    MediciNova Announces the Publication of Results of the Animal Model Study of MN‑166 (ibudilast) in Glioblastoma in Scientific Reports

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Scientific Reports has published results from the animal model study evaluating MN-166 (ibudilast) in glioblastoma (GBM). The article, “Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF),” is the first publication reporting the potential clinical utility of MN-166 (ibudilast) for GBM.

  • Zacks Small Cap Research2 months ago

    MNOV: Continuing to Plan for Phase 3 Studies in Progressive MS and ALS…

    MediciNova, Inc. (MNOV) is currently developing MN-166 (ibudilast) for a number of indications, with the lead programs being in progressive multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The company has completed Phase 2 clinical trials with positive results from both trial trials. Progressive MS: Previously, the company had reported positive results from the SPRINT-MS Phase 2b clinical trial of MN-166 in patients with progressive MS.

  • One Thing To Remember About The MediciNova, Inc. (NASDAQ:MNOV) Share Price
    Simply Wall St.2 months ago

    One Thing To Remember About The MediciNova, Inc. (NASDAQ:MNOV) Share Price

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Anyone researching MediciNova, Inc. (NASDAQ:MNOV) might wantRead More...

  • GlobeNewswire3 months ago

    MediciNova Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) and other Neurodegenerative Diseases

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

  • Benzinga3 months ago

    The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 8) Innoviva Inc (NASDAQ: INVA ) Organogenesis Holdings Inc ...

  • GlobeNewswire3 months ago

    MediciNova Announces Initiation of Enrollment in a Clinical Trial of MN-166 (ibudilast) in Glioblastoma

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the first glioblastoma patient has enrolled in the clinical trial of MN-166 (ibudilast) in combination with temozolomide (TMZ, Temodar‑®) for the treatment of recurrent glioblastoma (GBM). The principal investigators are Patrick Y. Wen, M.D., Professor of Neurology, Harvard Medical School and Director, Neuro-Oncology Division at the Dana-Farber Cancer Institute (DFCI) in Boston, and Kerrie McDonald, Ph.D., Associate Professor and Head of Biomarkers and Translational Research at the Lowy Cancer Research Centre, University of New South Wales, Australia.

  • GlobeNewswire4 months ago

    MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Japan

    MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the Japan Patent Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001)  for the treatment of “fibrosis” which includes a broad range of fibrosis / fibrotic disease in different organs due to different causes. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than June 2035. The allowed claims cover a composition for inhibiting or treating fibrosis using MN-001 or MN-002.

  • Simply Wall St.4 months ago

    Do Insiders Own Lots Of Shares In MediciNova, Inc. (NASDAQ:MNOV)?

    If you want to know who really controls MediciNova, Inc. (NASDAQ:MNOV), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of Read More...

  • GlobeNewswire4 months ago

    MediciNova to Present at the J.P. Morgan Healthcare Conference in San Francisco

    LA JOLLA, Calif., Dec. 12, 2018 -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock.

  • Zacks Small Cap Research6 months ago

    MNOV: MN-166 to be Studied in Degenerative Cervical Myelopathy…

    In August 2018, MediciNova, Inc. (MNOV) announced plans to conduct a Phase 2/3 trial of MN-166 in degenerative cervical myelopathy (DCM) through an agreement with the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust. The Principal Investigator is Dr. Mark Kotter and the trial is being funded by a grant from the National Institute for Health Research (NIHR) in the United Kingdom. MediciNova is not funding the trial but will provide the study drug supply, regulatory support, and safety monitoring support.

  • Benzinga7 months ago

    The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 3) Amarin Corporation plc (NASDAQ: AMRN ) BIOLINERX Ltd/S ...

  • Zacks Small Cap Research7 months ago

    MNOV: Positive FDA Feedback on ALS Phase 3 Plan…

    On September 25, 2018, MediciNova, Inc. (MNOV) announced that the FDA provided positive feedback in regards to the company’s development plan for MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS). The FDA did not raise any concerns with the safety of MN-166, only a single trial may be necessary if there is a statistically significant result when comparing MN-166 to placebo in a functional outcome (such as ALSFRS-R), and the agency would like to see a broad range of ALS patients with randomization stratified by baseline disease severity.